BRIEF-NOXXON Pharma signs clinical immuno-oncology collaboration agreement with MSD to study NOX-A12 combined with Keytruda (Pembrolizumab) in pancreatic and colorectal cancer
* Two companies will collaborate in a Phase 1/2 clinical trial of NOXXON's ANTI-CXCL12
agent, NOX-A12, and MSD's anti-PD-1 inhibitor, Keytruda (Pembrolizumab)
No comments:
Post a Comment